中华普通外科杂志
中華普通外科雜誌
중화보통외과잡지
CHINESE JOURNAL OF GENERAL SURGERY
2011年
8期
651-654
,共4页
韩芸蔚%王欣%张斌%温绍艳%刘伟%曹旭晨
韓蕓蔚%王訢%張斌%溫紹豔%劉偉%曹旭晨
한예위%왕흔%장빈%온소염%류위%조욱신
乳腺肿瘤%中性粒细胞减少%抗肿瘤联合化疗方案%预后
乳腺腫瘤%中性粒細胞減少%抗腫瘤聯閤化療方案%預後
유선종류%중성립세포감소%항종류연합화료방안%예후
Breast neoplasms%Neutropenia%Antineoplastic combined chemotherapy protocol%Prognosis
目的 探讨新辅助化疗诱导的粒细胞减少症与采用蒽环类联合紫杉类新辅助化疗方案进行新辅助化疗患者的疗效及远期生存率之间的关系.方法 对接受4个周期蒽环类联合紫杉类新辅助化疗方案治疗的211例乳腺癌患者的资料进行回顾性分析.结果 211例中51(24.2%)例为嗜中性粒减少症患者,160(75.8%)例为非嗜中性粒细胞减少症患者.嗜中性粒细胞减少症患者组的新辅助化疗反应较非嗜中性粒细胞减少症组患者为好(P＜0.05).嗜中性粒细胞减少症患者5年无病生存率为82.4%,5年总生存率为90.2%,而非嗜中性粒细胞减少症患者的5年无病生存率为60%,5年总生存率为67.5%,两者相比差异均有统计学意义(均P＜0.01).结论 蒽环类联合紫杉类新辅助化疗方案诱导的嗜中性粒细胞减少症与可手术乳腺癌患者的预后有良好的相关性,可用来评估肿瘤对此类化疗药物的敏感性,并为个体化的治疗方案提供依据.
目的 探討新輔助化療誘導的粒細胞減少癥與採用蒽環類聯閤紫杉類新輔助化療方案進行新輔助化療患者的療效及遠期生存率之間的關繫.方法 對接受4箇週期蒽環類聯閤紫杉類新輔助化療方案治療的211例乳腺癌患者的資料進行迴顧性分析.結果 211例中51(24.2%)例為嗜中性粒減少癥患者,160(75.8%)例為非嗜中性粒細胞減少癥患者.嗜中性粒細胞減少癥患者組的新輔助化療反應較非嗜中性粒細胞減少癥組患者為好(P＜0.05).嗜中性粒細胞減少癥患者5年無病生存率為82.4%,5年總生存率為90.2%,而非嗜中性粒細胞減少癥患者的5年無病生存率為60%,5年總生存率為67.5%,兩者相比差異均有統計學意義(均P＜0.01).結論 蒽環類聯閤紫杉類新輔助化療方案誘導的嗜中性粒細胞減少癥與可手術乳腺癌患者的預後有良好的相關性,可用來評估腫瘤對此類化療藥物的敏感性,併為箇體化的治療方案提供依據.
목적 탐토신보조화료유도적립세포감소증여채용은배류연합자삼류신보조화료방안진행신보조화료환자적료효급원기생존솔지간적관계.방법 대접수4개주기은배류연합자삼류신보조화료방안치료적211례유선암환자적자료진행회고성분석.결과 211례중51(24.2%)례위기중성립감소증환자,160(75.8%)례위비기중성립세포감소증환자.기중성립세포감소증환자조적신보조화료반응교비기중성립세포감소증조환자위호(P＜0.05).기중성립세포감소증환자5년무병생존솔위82.4%,5년총생존솔위90.2%,이비기중성립세포감소증환자적5년무병생존솔위60%,5년총생존솔위67.5%,량자상비차이균유통계학의의(균P＜0.01).결론 은배류연합자삼류신보조화료방안유도적기중성립세포감소증여가수술유선암환자적예후유량호적상관성,가용래평고종류대차류화료약물적민감성,병위개체화적치료방안제공의거.
Objective To evaluate the relationship between neoadjuvant chemotherapy (combination of taxanes and anthracyclines ) induced-neutropenia and the efficacy of neoadjuvant chemotherapy and long-term survival in operable breast cancer patients. Methods Two hundred and eleven patients received 4 cycles of neoadjuvant chemotherapy (combination of taxanes and anthracyclines).Clinicopathological characteristics were compared between patients with neoadjuvant chemotherapy-induced neutropenia and patients without neutropenia. The efficacy of neoadjuvant chemotheray and long-term survival rate were analyzed. Results Among 211 patients there were 51 (24. 2% ) cases suffering from neutropenia and 160 (75.8%) cases were of no-neutropenia. The response to chemotherapy in patients with neutropenia were more effective than in no- neutropenia ones ( P ＜ 0. 05 ). The 5-year disease-free survival (DFS) in patients with neutropenia was 82. 4%, while the 5-year disease-free survival ( DFS) with nonneutropenia was 60% ( P ＜ 0. 01 ). Additionally, the 5-year overall survival ( OS ) in patients with neutropenia was 90. 2% and in patients with non-neutropenia patients was 67. 5% ( P ＜ 0. 01 ).Conclusions Chemotherapy-induced neutropenia during neoadjuvant chemotherapy combination of taxanes and anthracyclines in patients with operable breast cancer has a better prognosis. The sensitivity of tumors given to chemotherapeutic drugs could be evaluated by chemotherapy-induced neutropenia.
